Havana, December 12 (RHC)-- Beginning in 2016, Cuban patients will benefit from a new Cuban Hepatitis B vaccine -HeberNasvac- following its approval by the country's Center for State Control of Drugs, Medical Equipment and Devices.

The announcement was made by Cuban experts, during Friday's closing session of the 2nd Conference on Research, Development and Innovation of Cuba's Bio-pharmaceutical Industry.

Developed by researchers with the Havana-based Center for Genetic Engineering and Biotechnology, the medication is an antigen that could be administered either through the nose or by subcutaneous injection. It is considered safer and more effective than those, which are currently used worldwide.